China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions has initiated the construction of a state-of-the-art biomacromolecules research and development (R&D) and manufacturing center in the Wai Gao Qiao Tax-Free Zone of Shanghai. This new facility aims to offer biopharmaceutical companies and new drug developers comprehensive one-stop CDMO services, from early clinical process development to pilot manufacturing, specifically for antibodies and antibody-drug conjugates (ADCs).
Anticipated Timeline and Synergy with Existing Services
The central process laboratory and production workshop of the new R&D and manufacturing center are scheduled to become operational between the third and fourth quarters of 2023. This expansion is expected to exert synergistic effects with the chemical synthesis service capabilities of Porton’s small molecule business units, Boyload and Linker, enhancing the company’s overall service offerings in the CDMO space.
Enhancing CDMO Services for Biopharmaceutical Innovation
By establishing this new center, Porton Pharma Solutions is poised to cater to the growing demand for specialized CDMO services in the biopharmaceutical industry. The facility will support the full spectrum of development needs, from early-stage research to the manufacturing of pilot batches, providing a seamless pathway for drug developers to bring their innovations to market.-Fineline Info & Tech
